The present invention relates to methods for purifying heterologous antibodies from caprine milk, such as goat milk. The present invention includes protein A based affinity chromatography to obtain purified transgenically expressed antibodies, in particular concentrates free from endogenous caprine antibodies.

The present invention relates to an antibody that binds specifically to the SARS CoV-2 spike protein, and methods for its manufacture.

The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.

Disclosed is a modified colostrum protein having an amino acid sequence shown in SEQ ID NO.: 1, which is generated by replacing Ile at position 33, Glu at position 101 and Arg at position 175 present in the amino acid sequence of a wild type colostrum protein shown in SEQ ID NO.: 2 respectively with Ala, Cys and Cys.

Disclosed herein are combination therapies comprising daratumumab and their uses.

The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.

Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a composition containing the monoclonal antibody. Compared with a fucosylated monoclonal antibody, the provided afucosylated monoclonal antibody has higher biological activity in vitro and in vivo and can be used for developing more effective therapeutic monoclonal antibody drugs.

The combination of specific immunoglobulins plus activated Bifidobacteria strains or other beneficial bacteria is described with the designed efficacy to colonize unstable microbiome communities in humans or other animals, restoring the keystone Bifidobacteria strains or other beneficial bacteria to compositional and functional importance in the intestine and improve overall health and reduce pathogenic infections in the host. Secretory immunoglobulin A (SIgA), when bound via specific glycans to select commensal bacteria grown on human milk oligosaccharides (HMOs), enhances the colonization potential of commensals through protection from intestinal digestion, enhancing attachment, and dampening host immune response.

Methods are provided for extracting and purifying maternal antibodies from breastmilk, followed by further processing to facilitate oral ingestion. The methods may be used on breastmilk from any mammal, including humans, for consumption by mammals including humans. Antibodies are well-known immune mediators that are naturally found in abundant supply in breastmilk, and they are passed directly to the offspring via breastfeeding. The methods described herein extract antibodies from breastmilk in a manner that preserves the structure and antigen-specificity while enabling the formulation into products that are optimized for delivery to mammals, including humans. The method comprises (1) breastmilk collection, (2) extraction of antibodies, (3) characterization of antibody structure, degradation, and contamination, and (4) formulation into a dietary supplement (food product) for delivery to mammals, especially humans.

The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.